uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On June 30, 2026, he sold a total of 30,000 Ordinary Shares in open-market sales at weighted average prices of $46.40 and $46.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised stock options to acquire 10,000 Ordinary Shares at a $5.59 exercise price, reducing his option position tied to that grant. Following these transactions, he directly owns 148,235 Ordinary Shares and holds 50,500 stock options expiring on March 1, 2034.
uniQure N.V. director Jack Kaye reported option exercises and share sales. On June 30, 2026, he exercised stock options for a total of 21,167 Ordinary Shares at exercise prices of $20.18 and $37.00, then sold the same number of shares in open-market transactions around $46.43–$46.49 per share. These trades were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on June 16, 2025. After these transactions, he directly owned 25,996 Ordinary Shares.
The filing provides notice of proposed sales of ordinary shares of UniQure N.V. by an affiliate, including a scheduled stock option exercise and sale of 21,082 shares on 07/02/2026 through Citigroup Global Markets for cash. The excerpt also lists multiple open-market sales by Matthew C. Kapusta during June 2026 with specific share counts and gross proceeds.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an open-market sale of 1,434 ordinary shares at a weighted average price of $46.86 per share. The shares were sold automatically upon vesting of restricted share units solely to cover estimated withholding taxes, and were not a discretionary trade. Following this transaction, he holds 168,235 shares directly.
Uniqure N.V. filed a Form 144 reporting proposed sales and recent dispositions of its Ordinary Shares. The filing lists a proposed sale of 30,000 Ordinary Shares through Citigroup Global Markets, Inc., dated 06/30/2026. It also records a 10,000-share option exercise under a Rule 10b5-1 plan on 06/30/2026 and 20,000 vested restricted shares on 06/26/2025. The filing shows past sales in the three months including 45,000 shares sold on 05/08/2026 for $1,127,435.50 and 1,434 shares sold on 06/26/2026 for $67,197.10.
Jack Kaye submitted a Form 144 reporting proposed sales of 21,167 Ordinary Shares on 06/30/2026, citing a stock option exercise pursuant to a 10b5-1 plan with cash proceeds. The filing lists three recent dispositions in June 2026 totaling 9,933 shares sold for cash.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported option exercises and share sales in Ordinary Shares. On June 24–25, 2026, he exercised stock options to acquire 32,844 shares at $31.71 per share and sold 35,412 shares in open-market transactions around $50 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 5, 2025. Following these transactions, he directly holds 519,227 Ordinary Shares.
UniQure N.V. reports proposed sale of 22,402 ordinary shares under vesting Restricted Stock Units, with an intended sale date of 06/26/2026. The filing also discloses a prior disposition of 45,000 ordinary shares by Walid Abi-Saab on 05/08/2026 for $1,127,435.50.
The 22,402 shares are tied to RSU vesting for services rendered; the filing lists Citigroup Global Markets, Inc. as a broker on the form. Timing and cash‑flow treatment for the new sale are those stated on the form.
Kapusta Matthew C reported a proposed sale of 28,716 ordinary shares of uniQure N.V. on 06/25/2026 via a stock option exercise and sale for cash.
The filing also lists recent sales by Kapusta in the prior three months, including 152,844 shares for $6,724,136.05 on 06/17/2026 and additional transactions on 06/18/2026 and 06/24/2026.
uniQure N.V. has priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, for expected gross proceeds of about $225 million. Underwriters exercised a 30-day option in full to buy an additional 741,758 shares at the same public price, less underwriting discounts and commissions.
The company estimates net proceeds from the offering of approximately $242.7 million after fees and expenses. The shares are being issued under an automatically effective Form S-3ASR shelf registration, with closing expected on or about June 25, 2026, subject to customary conditions.